A survey of 1,025 consumers conducted by remote patient monitoring company Vivalink Inc. found that 84% of respondents would be willing to participate in hospital-at-home monitoring if it allowed them to leave the hospital earlier. Further, of those who had participated in a hospital-at-home program, 84% reported a positive experience.
Aktiia SA recently received a CE mark for Calfree, its optical blood pressure monitoring technology that does not require calibration with a traditional cuff. The Calfree system can be integrated into a wide range of third-party devices, significantly improving hypertension management and as a result the quality of patients’ lives.
In May, the value of med-tech deals dropped to $85.78 million, marking a 50% decrease from April's $172.37 million but exceeding March's $27 million. The monthly average for deal value in 2024 now stands at $129.7 million, an 84% decline compared to the 2023 monthly average of $886.13 million.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Accure Acne, Emergency Scientific, Neusoft Medical, Positron, Quanta System, Venus Medtech.
The U.S. Supreme Court unanimously upheld the FDA’s relaxed regulation of the abortion drug mifepristone when it ruled June 13 that the organizations challenging those changes lacked the standing to do so.
The Biosecure Act missed its first chance at a congressional ride June 11 when the U.S. House Rules Committee didn’t include it, as many had expected, on the list of potential riders the House will consider for its version of the National Defense Authorization Act, a must-pass defense spending bill for fiscal 2025. But that doesn’t mean the bill will be stranded by the wayside.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aktiia, Cario, Providence Medical.
RSS
